drugset / Trial / NCT03055741

Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)

NCT03055741

Phase 2 Completed 180 enrolled Daehwa Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of DHP1401 in patients with mild-moderate Alzheimer's disease treated with donepezil

Timeline

Start
2016-12-28
Primary completion
2019-02
Completion
2019-08

Drugs

EvaluationDrugModalityDoseRoute
Subject DHP1401 Unknown 500 mg Oral
Subject DHP1401 Unknown 1000 mg Oral
Background Donepezil Small molecule 5 mg Oral
Background Donepezil Small molecule 10 mg Oral

Indications